RecruitingPhase 1Phase 2NCT06420076

Sequential CAR-T Cells Therapy for CD5/CD7 Positive T-cell Acute Lymphoblastic Leukemia and Lymphoblastic Lymphoma Using CD5/CD7-Specific CAR-T Cells

This is an Open, Single-arm, Clinical Study to Evaluate the Efficacy and Safety of Anti-CD7/CD5 CAR-T Cells in the Treatment of Relapsed or Refractory T-cell Acute Lymphoblastic Leukemia (T-ALL), ETP-ALL, and Lymphoblastic Lymphoma (TLBL).

Sponsor

Essen Biotech

Enrollment

60 participants

Start Date

Jul 10, 2024

Study Type

INTERVENTIONAL

Conditions

T-cell Lymphoma T-cell Prolymphocytic Leukemia T-cell Acute Lymphoblastic Leukemia T-cell Leukemia T-Cell Lymphoma of CNS T Cell Childhood ALL

Summary

Chimeric antigen receptor (CAR)-modified T cells targeted against CD19 have demonstrated unprecedented successes in treating patients with hematopoietic and lymphoid malignancies. Besides CD19, many other molecules such as CD22, CD30,BCMA,CD123, etc. may be the potential to develop the corresponding CAR-T cells to treat patients whose tumors express those markers. In this study, investigators will evaluate the safety and efficacy of Sequential CAR-T Cells Targeting CD5/CD7 in patients with patients with relapsed or refractory T-ALL/LBL/ETP-ALL. The primary goal is safety assessment including cytokine storm response and any other adverse effects. In addition, disease status after treatment will also be evaluated.

Eligibility

Min Age: 2 YearsMax Age: 90 Years

Inclusion Criteria9

Signed written informed consent; Patients volunteer to participate in the clinical trial;
Diagnosis is mainly based on the World Health Organization (WHO) 2008;
Complete remission cannot be achieved after induction therapy; recurrence occurs after completion remission; the burden of leukemic blasts in the peripheral blood or bone marrow is greater than 5%;
Leukemic blast cells express CD7/CD5 (CD7 OR CD5 positive by flow cytometry or immunohistochemistry ≥70%);
The expected survival period is greater than 12 weeks;
ECOG score ≤2;
Age 2-60 years old;
HGB≥70g/L (can be transfused);
Total bilirubin does not exceed 3 times the upper limit of normal value, and AST and ALT do not exceed 5 times the upper limit of normal value.

Exclusion Criteria9

Patients declining to consent for treatment
Prior solid organ transplantation
One of the following cardiac issues: atrial fibrillation; myocardial infarction within the past 12 months; prolonged QT syndrome or secondary QT prolongation; clinically significant pericardial effusion; cardiac insufficiency NYHA (New York Heart Association) III or IV;
History of severe pulmonary dysfunction diseases;
Severe infection or persistent infection cannot be effectively controlled;
Severe autoimmune disease or congenital immunodeficiency;
Active hepatitis;
Human immunodeficiency virus (HIV) infection;
Clinically significant viral infections, or uncontrollable viral reactivation, including EBV (Epstein-Barr virus).

Interventions

BIOLOGICALCD5/CD7 CAR-T

The intervention in this clinical trial involves a novel approach using CD5/CD7 Chimeric Antigen Receptor T (CAR T) cells combined with chemotherapy. The goal is to assess safety and efficacy in patients with specific hematologic malignancies. Treatment Regimen: Patients in the trial will undergo the following regimen: Fludarabine Phosphate (Days -4 to -2): IV administration of fludarabine phosphate over 30 minutes on days -4 to -2. It's part of the preparatory regimen to enhance the body's response to CAR T-cell therapy. Cyclophosphamide (Day -2): IV cyclophosphamide over 60 minutes on day -2. CD5/CD7 Chimeric Antigen Receptor T Cells (Day 0): IV administration of investigational therapy, CD5/CD7 CAR T cells, over 10-20 minutes on day 0. Additional Doses: Eligible patients responding well to the initial CD5/CD7 CAR-T cell infusion without unacceptable side effects and sufficient CAR-T cell availability may receive 2 or 3 additional doses.